Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 831

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 831
---
 current period other comprehensive loss                     | ​ | ​ | ​                                                 | ​ | -1,314 | ​ | ​ |
| Balance, December 31, 2022                                      | ​ | ​ | ​                                                 | $ | -1,672 | ​ | ​ |
| Other comprehensive income before reclassifications             | ​ | ​ | ​                                                 | ​ |  1,412 | ​ | ​ |
| Amount reclassified from accumulated other comprehensive loss   | ​ | ​ | ​                                                 | ​ |      — | ​ | ​ |
| Net current period other comprehensive income                   | ​ | ​ | ​                                                 | ​ |  1,412 | ​ | ​ |
| Balance, December 31, 2023                                      | ​ | ​ | ​                                                 | $ |   -260 | ​ | ​ |

F-57

TABLE OF CONTENTS

CARA THERAPEUTICS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data) Amounts reclassified out of accumulated other comprehensive (loss) income into net loss are determined by specific identification. The reclassifications out of accumulated other comprehensive (loss) income and into net loss were as follows:

| ​                                                             
 ​                                                             
 Component of Accumulated Other Comprehensive Income (Loss)    | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | ​                       
 Year Ended December 31, 
 2023                    | ​ | ​ | ​ | ​ 
 ​ | ​ 
 ​ | ​    
 2022 | ​ | ​ | ​ | ​ 
 ​ | ​ 
 ​ | ​    
 2021 | ​ |  ​ | ​ | ​ 
 ​ 
 ​ | ​ 
 ​ | ​                                                                     
 Affected Line Item in theConsolidated Statements ofComprehensive Loss | ​ 
 ​ |
|:--------------------------------------------------------------|:--|:--|:------------------------|:--|:--|:--|:--|:--|:-----|:--|:--|:--|:--|:--|:-----|:--|---:|:--|:--|:--|:----------------------------------------------------------------------|:--|
| Unrealized gains on available-for-sale marketable securities: | ​ | ​ | ​                       | ​ | ​ | ​ | ​ | ​ | ​    | ​ | ​ | ​ | ​ | ​ | ​    | ​ |  ​ | ​ | ​ | ​ | ​                                                                     | ​ |
|